Clinical research methodologies serve to demonstrate the efficacy and safety of new medicines. Alternatives to conventional methodologies in clinical research have been sought for years. However, novel methodologies have been rarely used for Market Access. Therefore, a call for expression of interest within the France 2030 investment plan intends to accelerate the availability of innovations for patients. As a matter of fact, new approaches in data, methods and tools can be especially useful for subpopulations with small sample size or with specific characteristics.
Dr. Meriem Bouslouk-Marx (MBM Future Health) evaluated within an international jury the value of new approaches in clinical research. The selected projects are use cases including artificial intelligence, synthetic control arms, real-world data mining and in silico trials. Most projects target rare cancers and rare diseases as a whole.
